Hunan Warrant Pharmaceutical (688799.SH): Ferrous Succinate Tablets and others are expected to be selected for national centralized drug procurement.

Hunan Warrant Pharmaceutical (688799.SH) announced that on July 31, 2026, the company participated in the bidding for the 12th national centralized procurement organized by the National Organization of Drug Procurement Office. The company's ferrous succinate tablets and diclofenac sodium sustained-release tablets are intended to be selected in this centralized procurement. This centralized procurement is the 12th national centralized drug procurement organized by the Joint Procurement Office. During the procurement period, medical institutions will prioritize the use of selected drugs and ensure that the agreed procurement volume is met. The proposed selection prices for the above products have decreased to a certain extent compared to the original selling prices. If the company subsequently signs procurement contracts and carries them out, it will facilitate the expansion of cooperation channels for the above products, promote the development of the domestic market, and enhance the company's brand influence.